Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $31.50.
Several brokerages recently weighed in on GTHX. BTIG Research began coverage on G1 Therapeutics in a research note on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price for the company. BidaskClub raised G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th.
G1 Therapeutics (NASDAQ:GTHX) opened at $23.04 on Friday. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67. The firm has a market capitalization of $585.33 and a PE ratio of -10.72.
Several large investors have recently added to or reduced their stakes in GTHX. RA Capital Management LLC acquired a new position in shares of G1 Therapeutics in the 2nd quarter valued at $46,813,000. FMR LLC purchased a new stake in G1 Therapeutics in the 2nd quarter worth about $34,093,000. Franklin Resources Inc. purchased a new stake in G1 Therapeutics in the 2nd quarter worth about $10,651,000. Hillhouse Capital Management Ltd. purchased a new stake in G1 Therapeutics in the 2nd quarter worth about $7,848,000. Finally, Laurion Capital Management LP purchased a new stake in G1 Therapeutics in the 2nd quarter worth about $3,488,000. Institutional investors and hedge funds own 43.25% of the company’s stock.
TRADEMARK VIOLATION WARNING: “G1 Therapeutics Inc (GTHX) Receives Consensus Rating of “Buy” from Brokerages” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/13/g1-therapeutics-inc-gthx-receives-consensus-rating-of-buy-from-brokerages.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.